

Functional Assessment Helps Behavioral Treatment

BY HEIDI SPLETE
Senior Writer

BALTIMORE — A functional assessment of behavior problems in children with developmental disabilities helps clinicians form a hypothesis for why a problem behavior occurs and what reinforces it, so they can use the information to guide treatment, according to a behavioral scientist at the Kennedy Krieger Institute, Baltimore. “Functional assessment has been found

to be the one factor that predicts successful behavioral treatment of maladaptive behaviors,” regardless of functional level, age, or type of behavior, Theodosia Paclawskyj, Ph.D., said at a meeting on developmental disabilities sponsored by Johns Hopkins University. Three tools for making functional assessment are interviews with parents, structured checklists, and direct observation of the child’s behavior. These methods are best used together to obtain

a complete picture of the situation, Dr. Paclawskyj explained. Use the interview as the initial step in assessing behavior problems, she said. A functional assessment interview includes these questions: ▶ When does the behavior always occur? ▶ When does the behavior never occur? ▶ What happens just before and just after the behavior? ▶ Are certain times or certain activities more likely to prompt the behavior?

▶ What do you think the child is trying to communicate through the behavior? ▶ Does the child appear to want a reaction from you after the behavior? ▶ Does the child avoid demands as a result of the behavior? ▶ Does the child exhibit more of the behavior when he or she must wait for something? ▶ Does the child exhibit this behavior even if he or she is alone? ▶ Does the child engage in the behavior in a repetitive way?

Structured checklists, such as the Motivation Assessment Scale and the Functional Analysis Screening Tool, have the advantage of being efficient with no risk to the patient. But the psychometric properties of checklists may be inconsistent, so they should only be used as one component of an overall functional assessment, along with interviews and observation, Dr. Paclawskyj said.

When it comes to observing a behavior directly, consider positive and negative reinforcement as motivations for external (social) and internal (nonsocial) behaviors.

In positive reinforcement, adding a stimulus causes a behavior to increase, but in negative reinforcement, the removal of a stimulus causes a behavior to increase.

“Many people misinterpret negative reinforcement as punishment,” Dr. Paclawskyj said. “Also, positive doesn’t always mean good; it means the person gets something as a result of their behavior.”

Potential functions of external/social behaviors—from the child’s perspective—include getting attention. “Remember that attention is any kind of response from another person,” said Dr. Paclawskyj. Receiving any sort of attention or receiving a tangible object or activity are types of positive reinforcement for a social behavior. Escape from the demands of a difficult task or relief from an undesirable situation are types of negative reinforcement for a social behavior.

The potential functions of internal/nonsocial behaviors are harder to assess, Dr. Paclawskyj noted. But positive reinforcement for these behaviors includes sensory stimulation and the release of endorphins, which have been linked to some forms of self-injury. The removal of physical or other discomfort is a type of negative reinforcement for a nonsocial behavior.

Once a clinician has observed a child’s behavior, he or she can use functional analysis to prompt the child to demonstrate the behavior to help determine the causes and develop treatments. Dr. Paclawskyj cited data from a study of children with Lesch-Nyhan syndrome, a disorder in which biting the lips, cheeks, and fingers are common self-injury behaviors. In this study, functional assessment showed that self-injury was more likely to occur during times of low social interaction (Dev. Med. Child Neurol. 2001;43:745-9).

Functional assessment and analysis don’t involve much subjective interpretation, said Dr. Paclawskyj. “We use research techniques to get a good understanding of the relationship between stimuli and behavior and between consequences and behavior,” she explained. ■

MAXAIR® AUTOHALER®

(pirbuterol acetate inhalation aerosol)

For Oral Inhalation Only

Brief Summary of Prescribing Information
See Package Insert for Full Prescribing Information

INDICATIONS AND USAGE MAXAIR AUTOHALER is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma. It may be used with or without concurrent theophylline and/or corticosteroid therapy. **CONTRAINDICATIONS** MAXAIR AUTOHALER is contraindicated in patients with a history of hypersensitivity to pirbuterol or any of its ingredients. **WARNINGS** **Cardiovascular:** MAXAIR AUTOHALER, like other inhaled beta adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure and/or symptoms. Although such effects are uncommon after administration of MAXAIR AUTOHALER at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, MAXAIR AUTOHALER, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. **Paradoxical Bronchospasm:** MAXAIR AUTOHALER can produce paradoxical bronchospasm, which can be life threatening. If paradoxical bronchospasm occurs, MAXAIR AUTOHALER should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister or vial. **Use of Anti-Inflammatory Agents:** The use of beta adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids. **Deterioration of Asthma:** Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of MAXAIR AUTOHALER than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. **PRECAUTIONS General:** Since pirbuterol is a sympathomimetic amine, it should be used with caution in patients with cardiovascular disorders, including ischemic heart disease, hypertension, or cardiac arrhythmias, in patients with hyperthyroidism or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines or who have convulsive disorders. Significant changes in systolic and diastolic blood pressure could be expected to occur in some patients after use of any beta adrenergic aerosol bronchodilator. Beta adrenergic agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation. **Information for Patients:** The action of MAXAIR AUTOHALER should last up to five hours or longer. MAXAIR AUTOHALER should not be used more frequently than recommended. Do not increase the dose or frequency of MAXAIR AUTOHALER without consulting your physician. If you find that treatment with MAXAIR AUTOHALER becomes less effective for symptomatic relief, or your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While you are using MAXAIR AUTOHALER, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, tremor or nervousness. If you are pregnant or nursing, contact your physician about use of MAXAIR AUTOHALER. Effective and safe use includes an understanding of the way the medication should be administered. As with all aerosol medications, it is recommended to prime (test) MAXAIR AUTOHALER before using for the first time. MAXAIR AUTOHALER should also be primed if it has not been used in 48 hours. As described in the priming procedure, use the test fire slide to release two priming sprays into the air away from yourself and other people. (See “Patient’s Instructions For Use” portion of this package insert.) The MAXAIR AUTOHALER actuator should not be used with any other inhalation aerosol canister. In addition, canisters for use with MAXAIR AUTOHALER should not be utilized with any other actuator. **Drug Interactions:** Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects. **Monoamine Oxidase Inhibitors or Tricyclic Antidepressants:** Pirbuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of pirbuterol on the vascular system may be potentiated. **Beta Blockers:** Beta adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as MAXAIR AUTOHALER, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta blockers could be considered, although they should be administered with caution. **Diuretics:** The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics. **Carcinogenesis, Mutagenesis and Impairment of Fertility:** In a 2-year study in Sprague-Dawley rats, pirbuterol hydrochloride administered at dietary doses of 1.0, 3.0, and 10 mg/kg (approximately 3, 10, and 35 times the maximum recommended daily inhalation dose for adults and children on a mg/m² basis) showed no evidence of carcinogenicity. In an 18-month study in mice at dietary doses of 1.0, 3.0, and 10 mg/kg (approximately 2, 5, and 15 times the maximum recommended daily inhalation dose for adults and children on a mg/m² basis) no evidence of tumorigenicity was seen. Reproduction studies in rats administered pirbuterol hydrochloride at oral doses of 1, 3, and 10 mg/kg (approximately 3, 10, and 35 times the maximum recommended daily inhalation dose for adults on a mg/m² basis) revealed no evidence of impaired fertility. Pirbuterol dihydrochloride showed no evidence of mutagenicity in *in vitro* assays and host-mediated microbial (Ames) assays for point mutations and *in vivo* tests for somatic or germ cell effects following acute and subchronic treatment in mice (cytogenicity assays). **Teratogenic Effects – Pregnancy Category C:** Pirbuterol was not teratogenic in rats administered oral doses of 30, 100, and 300 mg/kg (approximately 100, 340, and 1000 times the maximum recommended daily inhalation dose for adults on a mg/m² basis). Pirbuterol was not teratogenic in rabbits administered oral doses of 30 and 100 mg/kg (approximately 200 and 680 times the maximum recommended inhalation dose for adults on a mg/m² basis). However, pirbuterol at an oral dose of 300 mg/kg (approximately 2000 times the maximum recommended daily inhalation dose in adults on a mg/m² basis) caused abortions and fetal death. There are no adequate and well-controlled studies in pregnant women. Pirbuterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Labor and Delivery:** Because of the potential for beta-agonist interference with uterine contractility, use of MAXAIR AUTOHALER for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.

Nursing Mothers: It is not known whether pirbuterol is excreted in human milk. Therefore, MAXAIR AUTOHALER should be used during nursing only if the potential benefit justifies the possible risk to the newborn. **Pediatric Use:** MAXAIR AUTOHALER is not recommended for patients under the age of 12 years because of insufficient clinical data to establish safety and effectiveness. **ADVERSE REACTIONS** The following rates of adverse reactions to pirbuterol are based on single- and multiple-dose clinical trials involving 761 patients, 400 of whom received multiple doses (mean duration of treatment was 2.5 months and maximum was 19 months). The following were the adverse reactions reported more frequently than 1 in 100 patients: **CNS:** nervousness (6.9%), tremor (6.0%), headache (2.0%), dizziness (1.2%). **Cardiovascular:** palpitations (1.7%), tachycardia (1.2%). **Respiratory:** cough (1.2%). **Gastrointestinal:** nausea (1.7%). The following adverse reactions occurred less frequently than 1 in 100 patients and there may be a causal relationship with pirbuterol: **CNS:** depression, anxiety, confusion, insomnia, weakness, hyperkinesia, syncope. **Cardiovascular:** hypotension, skipped beats, chest pain. **Gastrointestinal:** dry mouth, glossitis, abdominal pain/cramps, anorexia, diarrhea, stomatitis, nausea and vomiting. **Ear, Nose and Throat:** smell/taste changes, sore throat. **Dermatological:** rash, pruritus. **Other:** numbness in extremities, alopecia, bruising, fatigue, edema, weight gain, flushing. Other adverse reactions were reported with a frequency of less than 1 in 100 patients but a causal relationship between pirbuterol and the reaction could not be determined: migraine, productive cough, wheezing, and dermatitis.

The following rates of adverse reactions during three-month controlled clinical trials involving 310 patients are noted. The table does not include mild reactions.

PERCENT OF PATIENTS WITH MODERATE TO SEVERE ADVERSE REACTIONS

Reaction	Pirbuterol N=157	Metaproterenol N=153
Central Nervous System		
tremors	1.3%	3.3%
nervousness	4.5%	2.6%
headache	1.3%	2.0%
weakness	.0%	1.3%
drowsiness	.0%	0.7%
dizziness	0.6%	.0%
Cardiovascular		
palpitations	1.3%	1.3%
tachycardia	1.3%	2.0%
Respiratory		
chest pain/tightness	1.3%	.0%
cough	.0%	0.7%
Gastrointestinal		
nausea	1.3%	2.0%
diarrhea	1.3%	0.7%
dry mouth	1.3%	1.3%
vomiting	.0%	0.7%
Dermatological		
skin reaction	.0%	0.7%
rash	.0%	1.3%
Other		
bruising	0.6%	.0%
smell/taste change	0.6%	.0%
backache	.0%	0.7%
fatigue	.0%	0.7%
hoarseness	.0%	0.7%
nasal congestion	.0%	0.7%

Electrocardiograms: Electrocardiograms, obtained during a randomized, double-blind, cross-over study in 57 patients, showed no observations or findings considered clinically significant, or related to drug administration. Most electrocardiographic observations, obtained during a randomized, double-blind, cross-over study in 40 patients, were judged not clinically significant or related to drug administration. One patient was noted to have some changes on the one hour postdose electrocardiogram consisting of ST and T wave abnormality suggesting possible inferior ischemia. This abnormality was not observed on the predose or the six hours postdose ECG. A treadmill was subsequently performed and all the findings were normal. **OVERDOSAGE** The expected symptoms with overdosage are those of excessive beta-stimulation and/or any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Hypokalemia may also occur. As with all sympathomimetic aerosol medication, cardiac arrest and even death may be associated with abuse of MAXAIR AUTOHALER. Treatment consists of discontinuation of pirbuterol together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage. The oral median lethal dose of pirbuterol dihydrochloride in mice and rats is greater than 2000 mg/kg (approximately 3400 and 6800 times the maximum recommended daily inhalation dose for adults on a mg/m² basis).

Note: The indented statement below is required by the Federal government’s Clean Air Act for all products containing or manufactured with chlorofluorocarbons (CFC’s).

WARNING: Contains trichloromonofluoromethane and dichlorodifluoromethane, substances which harm public health and environment by destroying ozone in the upper atmosphere.

A notice similar to the above WARNING has been placed in the “Patient’s Instructions For Use” portion of this package insert under the Environmental Protection Agency’s (EPA’s) regulations. The patient’s warning states that the patient should consult his or her physician if there are questions about alternatives.

This is only a brief summary of important information regarding MAXAIR AUTOHALER. For more information please visit www.maxairautohaler.com or call 1-800-328-0255.

Rx only

Manufactured by
3M Pharmaceuticals
Northridge, CA 91324

Distributed by
Graceway™ Pharmaceuticals, LLC
Bristol, TN 37620

654800

US19 Rev0407-1